Star Explorer


Star Picker


Star Viewer


Star Linker



HT-X Science

Cardio-regeneration Innovation Center, CRIC


Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality, affecting an estimated 38 million patients worldwide. It has become a major burden in developed countries because of its substantial readmission rate, poor prognosis, and increasing prevalence with population aging, the rising prevalence of lifestyle risk factors, improved outcomes of acute cardiac conditions, and improvements in HF management. HF is now becoming more common in China, where aging and high-income-country lifestyle changes lead to more risk factors for the development of HF. Transplantation of pluripotent stem cell-derived cardiomyocytes represents a regenerative therapeutic concept with great potential for the treatment of patients with heart failure. It was successfully applied in various preclinical studies and is currently evaluated in the first clinical trials (i.e., HEAL-CHF [Treating Heart Failure With hPSC-CMs], NCTO3763136).
Cited from Stüdemann Tim et al. Circulation 2022 and Hua Wang et al. Circulation 2021


Two-Track regulatory system for clinical stage
The clinical study of HiCM-188 was filed by National Health Commission of China collaborated with Prof. Dongjin WANG (Nanjing Drum Tower Hospital) in 2021(Certification No.MR-32-21- 014649).
IND was submitted both in China and US in 2022.
iPSC-drived cardiomyocyte products were issued by China National Institutes for Food and Drug Control (SH202005071).


International Advisor
Prof. Philippe Menasché, Chief Scientific Advisor
Professor of the UAB Department of Biomedical Engineering, clinical cardiac surgeon at the Hôpital Européen Georges Pompidou, Professor of Thoracic and Cardiovascular Surgery at the University of Paris Descartes
Prof. Emerson Perin
Provided leadership at the Texas Heart Institute for over 25 years, world-renowned cardiologist known for his leadership in the development of stem cell therapies for cardiovascular diseases, Director of the Center for Clinical Research, Director of the Stem Cell Center and the Medical Director of THI, at the Texas Heart Institute
Prof. Daniel Burkhoff
Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation. Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure
Domestic Advisor
Prof. Junbo GE
Academician of the Chinese Academy of Sciences, Dean of the Shanghai Institute of Cardiovascular Diseases, Dean of the First Hospital affiliated to the University of Science and Technology of China
Prof. Zhongmin LIU
Honorary Dean of the Shanghai East Hospital, Academician of the Russian Academy of Engineering
Prof. Dongjin WANG
Professor of cardiovascular surgery, the Director of the Department of Cardiothoracic Surgery at the Nanjing Drum Tower Hospital, awarded the Best Cardiac Surgeon in China (Gold Knife Award) in 2008
Prof. Huangtian YANG
Professor, Principal Investigator at the Shanghai Institute of Nutrition and Health, CAS
Prof. Jay WANG
Professor at the Jiangsu Province hospital & Jiangsu Clinical Research Institution
Prof. Xinli LI
Professor at the Nanjing Medical University, vice president at the Hypertension division of the Chinese Society of Cardiovascular Diseases, former vice president at the Heart Failure division of the Chinese Society of Cardiovascular Diseases

Joint lab of ophthalmic diseases, OD Lab


AMD is one of the major causes of vision loss among people aged 50 years and older. It is a polygenic disease with aging and cigarette smoking as key risk factors that trigger risk alleles to manifest with age. The advanced stage of AMD, geographic atrophy (GA), leads to vision loss and often blindness, is characterized by irreversible degeneration of the photoreceptors and retinal pigment epithelium (RPE).

In recent years, a paper on Cell Stem Cell confirmed that RPE cells differentiated from induced pluripotent stem cells (iPSC) were not rejected by the immune system. RPE holds great promise for the treatment of AMD.

Cited from Ruchi Sharma et al. Nat Commun. 2021


Help Thera-X, a leading global iPSC-derived cell therapy provider, announced a partnership with University of Macau to set up a new lab in Zhuhai City for regenerative medicine research. This five-year partnership is devoted to exploring cutting-edge application of iPsC-derived cell products.

The translational research and research on preclinical efficacy based on "iPSC-derived RPE for the treatment of AMD" collaborated with Jiangsu Province Hospital were honored as 2022 Jiangsu Provincial S&T Program and Nanjing Life Science Project.


Joint lab with University of Macau

Jiangsu Province Hospital

iPSC-driven Neuroscience Lab, iN Lab


Parkinson's disease is the second largest neurodegenerative diseases. Its cardinal features include motor symptoms such as bradykinesia, rigidity, resting tremor and postural instability, though nonmotor symptoms are often also present. Current pharmacologic therapy involves dopamine supplements, dopamine agonists, and antagonists inhibiting dopamine degradation. These treatments gradually lose their effectiveness with long-time use, where cell therapy, on the other hand, holds the promise. Cell transplantation with fetal tissue has been proved to be effective for treating PD during the last four decades. Despite of fetal tissue, iPsC-derived dopamine cells take advantage of reliable cell resource and no ethical concerns, and have been applied from bench to bedside.

Cited from Jinghua Piao et al. Cell Stem Cell. 2021


Help Thera-X, based on its patent — recombinant lentivirus-induced differentiation of neural stem cells into dopaminergic neurons (CN201310229277.7),cooperated with research institutes such as Nantong University to continuously explore clinical application of neural stem cell in treating PD.


Prof. Guokai CHEN
Professor, Associate Dean at the Faculty of Health Sciences, University of Macau

Motor Rehabilitation Lab, MR Lab

Motor System

Mesenchymal stem cell (MSC) is an ideal cell source for tissue regeneration. MSCs exist in almost all tissues, such as bone marrow, adipose tissue, and synovium, and are easily extracted. MSCs are multipotent, which means they have the ability to differentiate into many kinds of cell types within a lineage. MSCs exert an effect on a range of cells involved in the immune response and have been used as an immuse tolerant agent because of the effects like anti-inflammatory, immunoregulatory, and immunosuppressive capacities. Proven to be safe and effective, MSC therapy has been qranted reaulatory approval in several countries.

Cited from Yu Hanet al. Cell. 2019


Help Thera-X holds the cutting-edge technology in manufacturing cell products. With our automatic Cell Foundry platform, we continuously produce cells with high quality and low cost to meet the needs on the market.


Prof. Xiaoning WANG
First and Honorary Dean of the School of Biological Science and Engineering, South China University of Technology, Former Director of the Aging Institute, Chinese PLA General Hospital
Prof. Hua LIN
Chief Physician/Professor of Orthopedics Department, Nanjing Drum Tower Hospital

HT-X Talent

Star makers/pickers to transform great ideas into valuable therapeutic products.

What They Say

Prof. Charles Murry
Famous cardiologist at the University of Washington

That there is a trial ongoing in China came as a surprise to many, who didn't know that researchers there had overcome one of the field's biggest challenges — the need to produce large numbers of iPs-cell-derived cardiomyocytes that are pure enough to be used in people. This takes a lot of time and effort to get right, so very few companies or research groups have successfully done it.

Nature. 2020 May: 581(7808):249-250
Prof. Songtao YUAN
Ophthalmology Department, Jiangsu Province Hospital

Help Cell-foundry ensures the safety and consistency of producing transplanted cells. The Ophthalmology Department of Jiangsu Province Hospital also has a superior basic and clinical platform for ophthalmology. Our cooperation will promote translational research, and its strategic value and social benefits are considerable.

Prof. Dongjin WANG
Cardiovascular Disease Center, Nanjing Drum Tower Hospital

My goal is to assess the safety and efficacy of cell injection, and it was very encouraging when my patients get better after surgery. Tumor could be a main concern when we talk about cell therapy, but we have not encountered one yet. Meanwhile, our cell injection did not cause sustained dysfunction in heart rhvthm.

Nature. 2020 May:581 (7808):249-250.
Prof. Qinghai LIU
Ophthalmology Department, Jiangsu Province Hospital

It is of great clinical value to develop safe, effective cell products without ethical concerns as early as possible. Help Thera-X holds the technology in iPSC, while Jiangsu Province Hospital has rich clinical experience. Together we can bring cell therapy from the bench to the bedside.

Prof. Xinli LI
Cardiovascular Department, Jiangsu Province Hospital

Myocardial regeneration is a hot research field, and iPSC-derived cardiac cells hold the promise for patients who suffer from heart failure and eager for heart transplantation. I'm glad to see projects using iPSC-derived cardiomyocytes to treat heart failure got launched in China, and I sincerely hope these projects go well.

Prof. Minglong CHEN
Cardiovascular Department, Jiangsu Province Hospital

Heart failure is an unconquered battlefield that burdens families and our society heavily. For the treatment of end-stage heart failure, there is no truly effective treatment except heart transplantation. But most of the patients died waiting for the surgery; that's why exploring more effective treatment modalities is so urgent. Help Thera-X is the first company in China to use iPSC for cell therapy and has accumulated rich clinical experience in treating heart failure. I hope Help Thera-X will provide professional cell therapy services for millions of heart failure patients in China soon.

HT-X Update

Star viewer shows the latest achievements in scientific research and the application of regenerative medicine.It is also a platform to exhibit our cooperation with other enterprises.


Help Thera-X Institute collaborates with universities and institutes world widely to promote the application of cell therapy especially on degenerative diseases that have no good treatment options yet.
Research Cooperation

University of Macau

University of Macau Joint Lab
Help (Zhuhai) Innovation Center

Help Thera-X-University of Macau Joint Lab is a collaborative R&D lab founded by Help-Thera X and Zhuhai UM Science & Technology Research Institute (ZUMRI). The joint lab locates in the Traditional Chinese Medicine Science and Technology Industrial Park of Co-operation between Guangdong and Macao in Hengqin. The joint lab is operated by members from Help-Thera X and Prof. Guokai CHEN (Assistant Dean, Faculty of Health Sciences, UM), together with staff from ZUMRI.

This joint lab aims to deepen the collaboration among industry, academia and research institutes, accelerate technology transfer of research achievements in stem cell biology and clinical application, and promote the development of related industries through joint R&D projects and exchange programs.

Oujiang Laboratory

Zhejiang Lab For Regenerative Medicine, Vision And Brain Health

The Oujiang Laboratory was officially inaugurated by Zhejiang government and is located in the core area of the National Independent Innovation Demonstration Zone - ZheNan Science and Technology City. The lab focused on regeneration regulation and eye & brain health, the construction principle is "focusing on the frontier, domestically and globally".

Help-Thera X-Oujiang Joint Lab aims to break through vital technical and scientific issues and explore new biomaterials and biotechnology in treating cardiovascular diseases using stem cell technology.

Hospital Cooperation

Nanjing Drum Tower Hospital

The First Affiliated Hospital of Air Force Medical University

Shanghai East Hospital

The Second Xiangya Hospital of Central South University

Beijing Hospital

Teda International Cardiovascular Hospital

Guangdong Provicial People's Hospital